 Alice Weaver
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 527 | 1.540 |
Why?
| | Human papillomavirus 16 | 2 | 2024 | 33 | 1.390 |
Why?
| | Papillomavirus Infections | 2 | 2024 | 290 | 1.110 |
Why?
| | Career Choice | 3 | 2022 | 211 | 1.070 |
Why?
| | Carcinoma, Squamous Cell | 5 | 2017 | 626 | 0.930 |
Why?
| | Salivary Gland Neoplasms | 1 | 2023 | 32 | 0.820 |
Why?
| | Personnel Selection | 1 | 2019 | 72 | 0.620 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 833 | 0.590 |
Why?
| | Students, Medical | 2 | 2019 | 308 | 0.580 |
Why?
| | Fibroblast Growth Factor 1 | 1 | 2016 | 12 | 0.530 |
Why?
| | Education, Medical, Graduate | 2 | 2022 | 435 | 0.520 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2016 | 48 | 0.520 |
Why?
| | Receptor, Notch1 | 1 | 2016 | 62 | 0.510 |
Why?
| | Schools, Medical | 1 | 2017 | 129 | 0.510 |
Why?
| | Mouth Neoplasms | 1 | 2016 | 86 | 0.500 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2015 | 89 | 0.490 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2015 | 36 | 0.490 |
Why?
| | Calcium-Binding Proteins | 1 | 2016 | 213 | 0.480 |
Why?
| | Biomedical Research | 2 | 2022 | 654 | 0.470 |
Why?
| | Robotic Surgical Procedures | 1 | 2016 | 109 | 0.470 |
Why?
| | DNA Repair | 2 | 2015 | 208 | 0.470 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 89 | 0.460 |
Why?
| | Communication | 1 | 2019 | 839 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 952 | 0.350 |
Why?
| | Curriculum | 1 | 2017 | 925 | 0.340 |
Why?
| | Internship and Residency | 1 | 2019 | 1052 | 0.330 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2024 | 10 | 0.230 |
Why?
| | Oncogene Proteins, Viral | 1 | 2024 | 22 | 0.230 |
Why?
| | Salivary Glands | 1 | 2023 | 25 | 0.210 |
Why?
| | Gene Fusion | 1 | 2023 | 24 | 0.210 |
Why?
| | Survival Analysis | 2 | 2016 | 1283 | 0.210 |
Why?
| | Cancer Vaccines | 1 | 2024 | 164 | 0.200 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2015 | 422 | 0.200 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 203 | 0.200 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 175 | 0.190 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 543 | 0.180 |
Why?
| | Physicians | 2 | 2022 | 848 | 0.180 |
Why?
| | Repressor Proteins | 1 | 2024 | 400 | 0.180 |
Why?
| | Mice, Inbred NOD | 2 | 2023 | 579 | 0.160 |
Why?
| | Immunotherapy | 1 | 2023 | 584 | 0.150 |
Why?
| | Prognosis | 2 | 2016 | 3793 | 0.150 |
Why?
| | Female | 7 | 2024 | 68274 | 0.140 |
Why?
| | Alabama | 1 | 2017 | 37 | 0.140 |
Why?
| | Humans | 11 | 2024 | 129078 | 0.130 |
Why?
| | Cetuximab | 1 | 2017 | 93 | 0.130 |
Why?
| | Pyrazines | 1 | 2017 | 88 | 0.130 |
Why?
| | Biopsy, Needle | 1 | 2016 | 192 | 0.130 |
Why?
| | Comet Assay | 1 | 2015 | 20 | 0.130 |
Why?
| | Tumor Suppressor p53-Binding Protein 1 | 1 | 2015 | 13 | 0.130 |
Why?
| | Papillomaviridae | 1 | 2016 | 112 | 0.130 |
Why?
| | Homologous Recombination | 1 | 2015 | 23 | 0.130 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 425 | 0.120 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 207 | 0.120 |
Why?
| | BRCA1 Protein | 1 | 2015 | 63 | 0.120 |
Why?
| | Chromosomes | 1 | 2015 | 100 | 0.120 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 255 | 0.120 |
Why?
| | Middle Aged | 4 | 2024 | 31024 | 0.120 |
Why?
| | Mice, SCID | 1 | 2015 | 340 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2016 | 657 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 480 | 0.120 |
Why?
| | Universities | 1 | 2017 | 404 | 0.110 |
Why?
| | Benzimidazoles | 1 | 2015 | 158 | 0.110 |
Why?
| | DNA, Viral | 1 | 2016 | 380 | 0.110 |
Why?
| | Cell Line, Tumor | 3 | 2017 | 3114 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2017 | 1318 | 0.110 |
Why?
| | Pyrazoles | 1 | 2017 | 403 | 0.110 |
Why?
| | Analysis of Variance | 1 | 2016 | 1285 | 0.110 |
Why?
| | Male | 5 | 2024 | 63248 | 0.100 |
Why?
| | Signal Transduction | 2 | 2016 | 4867 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1697 | 0.100 |
Why?
| | Aged | 2 | 2024 | 22068 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 1966 | 0.090 |
Why?
| | Histones | 1 | 2015 | 584 | 0.090 |
Why?
| | Neoplasms | 1 | 2024 | 2429 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2017 | 14562 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2014 | 1102 | 0.080 |
Why?
| | Adult | 2 | 2024 | 35423 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2016 | 4927 | 0.070 |
Why?
| | Phenotype | 1 | 2015 | 3062 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 3290 | 0.070 |
Why?
| | Apoptosis | 1 | 2015 | 2485 | 0.070 |
Why?
| | Mice | 3 | 2023 | 16583 | 0.070 |
Why?
| | Cohort Studies | 1 | 2016 | 5400 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2043 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5365 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2017 | 10256 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2357 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 225 | 0.050 |
Why?
| | Animals | 3 | 2023 | 34708 | 0.050 |
Why?
| | Minority Groups | 1 | 2022 | 240 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2022 | 198 | 0.040 |
Why?
| | United States | 1 | 2016 | 13992 | 0.040 |
Why?
| | Checkpoint Kinase 2 | 1 | 2017 | 22 | 0.030 |
Why?
| | Checkpoint Kinase 1 | 1 | 2017 | 30 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 354 | 0.030 |
Why?
| | Myristoylated Alanine-Rich C Kinase Substrate | 1 | 2014 | 6 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2014 | 55 | 0.030 |
Why?
| | Molecular Mimicry | 1 | 2014 | 37 | 0.030 |
Why?
| | Radiation, Ionizing | 1 | 2014 | 75 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 377 | 0.030 |
Why?
| | Radiation Tolerance | 1 | 2014 | 97 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 799 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1213 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1085 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 835 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 382 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2050 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2014 | 694 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1686 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2846 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2344 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2014 | 898 | 0.020 |
Why?
| | Mutation | 1 | 2014 | 3679 | 0.010 |
Why?
|
|
Weaver's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|